Skip to main content
. 2021 Apr 28;373:n808. doi: 10.1136/bmj.n808

Table 4.

Effect of antibiotic prescribing strategy on all clinical outcomes in one stage random effects IPD meta-analysis. Values are means (95% confidence intervals) unless stated otherwise

Outcome Delayed v no antibiotics Delayed v immediate antibiotics
No of participants (none) No of participants (delayed) No antibiotics Delayed Adjusted* estimate (95% CI) No of participants (immediate) No of participants (delayed) Immediate Delayed Adjusted* estimate (95% CI)
Follow-up symptom severity score on days 2-4
RCT+OS 2716 1192 2.499 (1.44 to 3.56) 2.496 (1.47 to 3.52) −0.003 (−0.12 to 0.11) 2699 1053 2.68 (1.26 to 4.11) 2.70 (1.36 to 4.05) 0.02 (−0.11 to 0.15)
RCT 484 815 2.77 (1.13 to 4.11) 2.86 (1.6 to 4.06) 0.09 (−0.10 to 0.28) 606 674 2.29 (0.66 to 3.93) 2.40 (0.78 to 4.03) 0.11 (−0.004 to 0.22)
OS 2232 377 2.22 (1.86 to 2.59) 2.12 (1.74 to 2.50) −0.10 (−0.12 to −0.08)† 2093 379 2.75 (2.24 to 3.26) 2.63 (2.05 to 3.20) −0.12 (−0.33 to 0.07)
Time to complete symptom resolution (days)
RCT+OS 3091 1123 11.5 (6.4 to 16.6) 11.6 (6.4 to 16.6) 1.00 (0.82 to 1.23)‡ 3275 1442 10.9 (6.3 to 15.6) 11.4 (6.8 to 15.9) 1.04 (1.01 to 1.08)†‡
RCT 540 647 9.42 (4.22 to 14.62) 9.88 (4.37 to 15.38) 1.04 (0.95 to 1.13) 876 962 9.94 (7.17 to 12.70) 11.37 (8.19 to 14.54) 1.14 (1.06 to 1.22)†
OS 2551 476 15.1 (14.8 to 15.4) 15.5 (15.2 to 15.8) 0.98 (0.94 to 1.01) 2399 480 11.96 (5.90 to 18.03) 12.37 (6.40 to 18.35) 1.02 (0.97 to 1.07)‡
Duration of moderately severe or severe symptoms (days)
RCT+OS 2997 1251 6.2 (5.0 to 7.5) 6.3 (5.0 to 7.5) 1.01 (0.91 to 1.12) 2744 902 5.8 (4.5 to 7.2) 6.4 (5.3 to 7.6) 1.08 (1.01 to 1.17)†
RCT 447 775 6.88 (4.21 to 9.56) 6.81 (4.16 to 9.46) 1.04 (0.94 to 1.15) 347 426 6.36 (5.85 to 6.86) 7.48 (6.94 to 8.02) 1.18 (1.06 to 1.31)†‡
OS 2550 476 6.59 (5.45 to 6.74) 6.74 (6.60 to 6.87) 0.97 (0.93 to 1.01) 2397 476 5.36 (4.02 to 6.70) 5.94 (4.86 to 7.02) 1.05 (0.96 to 1.16)‡
Reconsultation (%, 95% CI)
RCT+OS 16 232 5901 17 (4 to 58) 13 (2 to 52) 0.72 (0.60 to 0.87)† 22 430 6157 22 (4 to 58) 16 (3 to 59) 0.95 (0.74 to 1.22)
RCT 509 611 25 (15 to 22) 21 (10 to 31) 0.92 (0.67 to 1.26) 796 865 25 (5 to 41) 24 (8 to 41) 1.29 (0.84 to 1.99)
OS 15 723 5290 16 (4 to 60) 12 (2 to 54) 0.54 (0.49 to 0.60)† 21 634 5292 22 (4 to 58) 15 (3 to 59) 0.70 (0.66 to 0.75)†
Complication (hospital admission or death; %, 95% CI)
RCT+OS 16 364 5827 0.6 (0.03 to 14) 0.4 (0.02 to 11) 0.62 (0.30 to 1.27) 22 371 6017 0.8 (0.1 to 5) 0.6 (0.1 to 4) 0.78 (0.53 to 1.13)
RCT 431 530 0.6 (0.02 to 14) 2.09 (0.01 to 22) 0.35 (0.07 to 1.92) 650 719 0.9 (0.3 to 5) 1.0 (0.3 to 4) 1.25 (0.38 to 4.16)
OS 15 933 5297 0.6 (0.01 to 3.7) 0.4 (0.01 to 2.2) 0.64 (0.28 to 1.43) 21 721 5298 0.7 (0.3 to 1.7) 0.6 (0.2 to 1.6) 0.22 (0.19 to 0.27)†
Patient satisfaction score
RCT+OS 1434 674 2.96 (2.55 to 3.36) 3.04 (2.64 to 3.44) 0.09 (0.06 to 0.11)† 1743 805 2.99 (2.33 to 3.64) 2.87 (2.25 to 3.49) −0.12 (−0.26 to 0.03)
RCT 433 520 3.17 (2.82 to 3.51) 3.26 (2.92 to 3.60) 0.06 (−0.03 to 0.16) 563 649 3.20 (2.33 to 4.06) 3.07 (2.22 to 3.92) −0.13 (−0.31 to 0.05)
OS 1001 154 2.77 (2.15 to 3.39) 2.85 (2.25 to 3.46) 0.10 (−0.03 to 0.23) 1180 156 2.88 (2.07 to 3.69) 2.77 (2.01 to 3.52) −0.06 (−0.18 to 0.06)

Adjusted estimate=coefficient, odds ratio, or relative risk; IPD=individual patient data; OS=observational study; RCT=randomised controlled trial.

*

Adjusted for baseline severity, age, and condition.

Statistically significant result. The number of observations for each outcome varies as not all studies collected data on all outcomes; analyses used all available data for each outcome.

Estimated using fixed study specific effects and random treatment effect due to convergence difficulties.